Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. PANW
3. CL
4. SNDK
5. TAP
6. DELL
7. ROIV
8. ANET
9. NKE
10. BLDR

Go back to Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
AGIOS PHARM (NASDAQ: AGIO) Delayed: 33.10 -0.03 (0.09%)
Previous Close $33.13    52 Week High $71.49 
Open $33.13    52 Week Low $33.50 
Day High $33.50    P/E N/A 
Day Low $32.92    EPS $-1.18 
Volume 480,162